Acceder

Publicaciones - FARMACOCINETICA CLINICA Y FARMACOTERAPIA APLICADA

Cargando...
Iniesta-Navalon C, Rios-Saorin M, Rentero-Redondo L, Anez-Castano R, Urbieta-Sanz E. Comparative evaluation of point of care assay with ELISA techniques for quantifying serum concentrations of ustekinumab in inflammatory bowel disease patients. Gastroenterol Hepatol. 2024 Oct 21:S0210-5705(24)00284-X. doi: 10.1016/j.gastrohep.2024.502277. Online ahead of print. English, Spanish. PubMed PMID: 39442691.
AÑO: 2024; IF: 2.2
Anez-Castano R, Iniesta-Navalon C, Almanchel-Rivadeneyra M, Garcia-Villalba E, Oliver-Galera E, Rentero-Redondo L. Therapeutic drug monitoring of inhaled tobramycin in a patient with chronic kidney disease. Eur J Hosp Pharm. 2024 Aug 24:ejhpharm-2023-004075. doi: 10.1136/ejhpharm-2023-004075. Online ahead of print. PubMed PMID: 39181698.
AÑO: 2024; IF: 1.6
Iniesta Navalon C, Rios-Saorin M, Rentero-Redondo L, Nicolas-de Prado I, Gomez-Espin R, Urbieta Sanz E. Impact of ustekinumab exposure on clinical outcomes during induction in inflammatory bowel disease. Rev Esp Enferm Dig. 2024 Dec 4. doi: 10.17235/reed.2024.10521/2024. Online ahead of print. PubMed PMID: 39629805.
AÑO: 2024; IF: 2.7
Diaz LS, Navalon CI, Espin RG, Prado IN, Redondo LR. Impact of proactive of infliximab monitoring using the Bayesian approach in the maintenance phase in patients with inflammatory bowel disease. Gastroenterol Hepatol. 2023 Aug-Sep;46(7):504-511. doi: 10.1016/j.gastrohep.2022.10.019. Epub 2022 Nov 15. English, Spanish. PubMed PMID: 36400260.
AÑO: 2023; IF: 2.2
Serrano-Diaz L, Iniesta-Navalon C, Gomez-Espin R, Nicolas-de Prado I, Bernal-Morell E, Rentero-Redondo L. Impact of proactive therapeutic drug monitoring of infliximab during the induction phase in IBD patients. A Bayesian approach. Rev Esp Enferm Dig. 2023 Aug;115(8):435-443. doi: 10.17235/reed.2022.8781/2022. PubMed PMID: 36562529.
AÑO: 2023; IF: 2.7
Siguiente >

Instituto de Investigación Sanitaria Acreditado

ISCII

FARMACOCINETICA CLINICA Y FARMACOTERAPIA APLICADA